ERBB2 and neoplasm: Additionally, a correlation was noted between lower tumor heterogeneity and enhanced therapeutic sensitivity within the HER2-positive subgroup; specifically, 67.4% of patients in the low-heterogeneity group achieved a pCR versus 43.2% in the high-heterogeneity group (p = 0.023).